Development of nonviral vectors targeting the brain as a therapeutic approach for Parkinson's disease and other brain disorders

Hayate Javed, Sindhu A. Menon, Karima M. Al-Mansoori, Abdelmojib Al-Wandi, Nour Majbour, Mustafa T. Ardah, Shiji Varghese, Nishant Vaikath, M. Emdadul Haque, Mimoun Azzouz, Omar Ali El-Agnaf

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Parkinson's disease (PD) is a debilitating neurodegenerative disease characterized by tremor, rigidity, bradykinesia, and postural instability, for which there is no effective treatment available till date. Here, we report the development of nonviral vectors specific for neuronal cells that can deliver short interfering RNA (siRNA) against the α-synuclein gene (SNCA), and prevent PD-like symptoms both in vitro and in vivo. These vectors not only help siRNA duplexes cross the blood-brain barrier in mice, but also stabilize these siRNAs leading to a sustainable 60-90% knockdown of α-synuclein protein. Mice treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine rapidly develop PD-like symptoms which were significantly alleviated when SNCA was knocked down using our vectors. Together, our data not only confirm the central role of α-synuclein in the onset of PD, but also provide a proof of principle that these nonviral vectors can be used as novel tools to design effective strategies to combat central nervous system diseases.

Original languageEnglish
Pages (from-to)746-758
Number of pages13
JournalMolecular Therapy
Volume24
Issue number4
DOIs
Publication statusPublished - 1 Apr 2016

Fingerprint

Synucleins
Brain Diseases
Parkinson Disease
Brain
Small Interfering RNA
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
Hypokinesia
Central Nervous System Diseases
Tremor
Therapeutics
Blood-Brain Barrier
Neurodegenerative Diseases
Genes
Proteins

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics
  • Pharmacology
  • Drug Discovery

Cite this

Development of nonviral vectors targeting the brain as a therapeutic approach for Parkinson's disease and other brain disorders. / Javed, Hayate; Menon, Sindhu A.; Al-Mansoori, Karima M.; Al-Wandi, Abdelmojib; Majbour, Nour; Ardah, Mustafa T.; Varghese, Shiji; Vaikath, Nishant; Haque, M. Emdadul; Azzouz, Mimoun; Ali El-Agnaf, Omar.

In: Molecular Therapy, Vol. 24, No. 4, 01.04.2016, p. 746-758.

Research output: Contribution to journalArticle

Javed, Hayate ; Menon, Sindhu A. ; Al-Mansoori, Karima M. ; Al-Wandi, Abdelmojib ; Majbour, Nour ; Ardah, Mustafa T. ; Varghese, Shiji ; Vaikath, Nishant ; Haque, M. Emdadul ; Azzouz, Mimoun ; Ali El-Agnaf, Omar. / Development of nonviral vectors targeting the brain as a therapeutic approach for Parkinson's disease and other brain disorders. In: Molecular Therapy. 2016 ; Vol. 24, No. 4. pp. 746-758.
@article{f97390d9d9d044149ff1b2c0281c5608,
title = "Development of nonviral vectors targeting the brain as a therapeutic approach for Parkinson's disease and other brain disorders",
abstract = "Parkinson's disease (PD) is a debilitating neurodegenerative disease characterized by tremor, rigidity, bradykinesia, and postural instability, for which there is no effective treatment available till date. Here, we report the development of nonviral vectors specific for neuronal cells that can deliver short interfering RNA (siRNA) against the α-synuclein gene (SNCA), and prevent PD-like symptoms both in vitro and in vivo. These vectors not only help siRNA duplexes cross the blood-brain barrier in mice, but also stabilize these siRNAs leading to a sustainable 60-90{\%} knockdown of α-synuclein protein. Mice treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine rapidly develop PD-like symptoms which were significantly alleviated when SNCA was knocked down using our vectors. Together, our data not only confirm the central role of α-synuclein in the onset of PD, but also provide a proof of principle that these nonviral vectors can be used as novel tools to design effective strategies to combat central nervous system diseases.",
author = "Hayate Javed and Menon, {Sindhu A.} and Al-Mansoori, {Karima M.} and Abdelmojib Al-Wandi and Nour Majbour and Ardah, {Mustafa T.} and Shiji Varghese and Nishant Vaikath and Haque, {M. Emdadul} and Mimoun Azzouz and {Ali El-Agnaf}, Omar",
year = "2016",
month = "4",
day = "1",
doi = "10.1038/mt.2015.232",
language = "English",
volume = "24",
pages = "746--758",
journal = "Molecular Therapy",
issn = "1525-0016",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Development of nonviral vectors targeting the brain as a therapeutic approach for Parkinson's disease and other brain disorders

AU - Javed, Hayate

AU - Menon, Sindhu A.

AU - Al-Mansoori, Karima M.

AU - Al-Wandi, Abdelmojib

AU - Majbour, Nour

AU - Ardah, Mustafa T.

AU - Varghese, Shiji

AU - Vaikath, Nishant

AU - Haque, M. Emdadul

AU - Azzouz, Mimoun

AU - Ali El-Agnaf, Omar

PY - 2016/4/1

Y1 - 2016/4/1

N2 - Parkinson's disease (PD) is a debilitating neurodegenerative disease characterized by tremor, rigidity, bradykinesia, and postural instability, for which there is no effective treatment available till date. Here, we report the development of nonviral vectors specific for neuronal cells that can deliver short interfering RNA (siRNA) against the α-synuclein gene (SNCA), and prevent PD-like symptoms both in vitro and in vivo. These vectors not only help siRNA duplexes cross the blood-brain barrier in mice, but also stabilize these siRNAs leading to a sustainable 60-90% knockdown of α-synuclein protein. Mice treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine rapidly develop PD-like symptoms which were significantly alleviated when SNCA was knocked down using our vectors. Together, our data not only confirm the central role of α-synuclein in the onset of PD, but also provide a proof of principle that these nonviral vectors can be used as novel tools to design effective strategies to combat central nervous system diseases.

AB - Parkinson's disease (PD) is a debilitating neurodegenerative disease characterized by tremor, rigidity, bradykinesia, and postural instability, for which there is no effective treatment available till date. Here, we report the development of nonviral vectors specific for neuronal cells that can deliver short interfering RNA (siRNA) against the α-synuclein gene (SNCA), and prevent PD-like symptoms both in vitro and in vivo. These vectors not only help siRNA duplexes cross the blood-brain barrier in mice, but also stabilize these siRNAs leading to a sustainable 60-90% knockdown of α-synuclein protein. Mice treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine rapidly develop PD-like symptoms which were significantly alleviated when SNCA was knocked down using our vectors. Together, our data not only confirm the central role of α-synuclein in the onset of PD, but also provide a proof of principle that these nonviral vectors can be used as novel tools to design effective strategies to combat central nervous system diseases.

UR - http://www.scopus.com/inward/record.url?scp=84955595733&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84955595733&partnerID=8YFLogxK

U2 - 10.1038/mt.2015.232

DO - 10.1038/mt.2015.232

M3 - Article

C2 - 26700614

AN - SCOPUS:84955595733

VL - 24

SP - 746

EP - 758

JO - Molecular Therapy

JF - Molecular Therapy

SN - 1525-0016

IS - 4

ER -